The first patient was recently registered into the newly initiated EORTC trial 21081, a phase III study designed to determine if maintenance treatment with lenalidomide (Revlimid™) prolongs progression free survival in chemonaive patients with ad
Application is now open for Methods in C
Dr. Nicolas Penel recently completed a Research Fellowship at EORTC Headquarters. During his stay he became involved in a number of studies and projects, particularly with projects being conducted by the EORTC Soft Tissue Sarcoma Group (STBSG), Brain Tumor Group (BTG), and Endocrine Tumors Task Force (ETF).
Each year the International Society for Quality of Life (ISOQOL) recognizes the best presentations made by investigators in the early stages of their career in QOL research.
Professor Michel Bolla and coworkers have reported the final results of the EORTC 22863 trial, Phase III Randomized Comparison of Pelvic Radiotherapy Alone versus
The 2nd EORTC Symposium on Quality of life, Symptom Research, and Patient Reported Outcomes in Cancer Clinical Trials
With the essential support of the Vlaamse Liga tegen Kanker, the EORTC Emmanuel van der Schueren Fellowship plays a key role in developing quality assurance in radiotherapy (QA RT) techniques in the face of rapidly evolving technological challenges, performing QA RT-related research, and demonstrating that QA RT is an essential component of high quality radiotherapy delivery which affects not only patients within clinical trials but all cancer patients by promoting and improving radiotherapy standards.
